Vetoquinol SA (VETOF)

Market Cap	1.13B +15.2%
Revenue (ttm)	602.47M -0.9%
Net Income	71.78M +4.8%
EPS	6.10 +6.9%
Shares Out	n/a
PE Ratio	14.45
Forward PE	15.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	495
Open	88.17
Previous Close	90.80
Day's Range	88.17 - 88.19
52-Week Range	88.17 - 90.80
Beta	0.77
Analysts	n/a
Price Target	n/a
Est. Earnings	Mar 22, 2027

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA operates as a ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1933
• Employees: 2,526
• Stock Exchange: OTCMKTS
• Ticker Symbol: VETOF

Financial Performance

In 2025, Vetoquinol's revenue was 525.69 million, a decrease of -2.51% compared to the previous year's 539.20 million. Earnings were 57.36 million, a decrease of -2.26%.

Financial numbers in EUR

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 9, 2026

Data Sources Report a data error